VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$24.67
−0.52%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -7.9%
- EBIT
- -9.0%
- EPS
- +13.1%
- Free cash flow
- -8.2%
- Operating cash flow
- -7.9%
Forward estimates
Based on analyst estimates
- Revenue
- +214.3%
- EBITDA
- +26.2%
- EPS
- +19.3%
Three-year CAGR
- Revenue
- +241.9%
- EBITDA
- -26.6%
- EBIT
- -21.5%
- Net income
- -26.9%
- EPS
- +16.6%
- Free cash flow
- -18.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026